Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Womens Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

Published: Nov-2012 | Format: PDF | GBI Research | Number of pages: 137 | Code: MRS - 1302

GBI Research, a leading business intelligence provider, has released its latest research, “Women’s Health Therapeutics Market to 2018 Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy”, which provides insights into the women’s health therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. It provides an in-depth analysis of the major diseases, and includes coverage of menopause, postmenopausal osteoporosis, endometriosis, infertility, and female contraceptives. The report provides in-depth analysis of the drivers and barriers that affect the global women’s health market, and analyzes the markets for women’s health disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also analyzes the women’s health therapeutics market in India, China and Australia. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.

In 2011, the women’s health therapeutics market was estimated to be worth $18.8 billion. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 2.7% between 2011 and 2018, to record a sales value of $22.7 billion in 2018. The patent expiries of blockbusters such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and others during the forecast period are expected to slow down the market growth for the women’s health therapeutics market. The launch of novel molecules like Elagolix and Odanacatib in the late stage pipeline will drive the market in the forecast period.

The women’s health therapeutics market R&D pipeline shows promising molecules. The current treatment options for women’s disorders are limited due to lack of safety. The unmet need in the women’s disorders market is attracting the pharmaceutical companies to invest in R&D programs. Increased focus is seen on therapy areas such as menopause, female sexual dysfunction and infertility.

Scope

  • Annualized market data for the women’s health disorders market from 2003 to 2011, with forecasts to 2018.
  • Analysis of the leading therapeutic segments, including menopause, postmenopausal osteoporosis, endometriosis, infertility, and the female contraceptives market.
  • Analysis of the women’s health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan. 
  • Market characterization of the women’s health therapeutics market, including market size, annual cost of therapy and treatment usage patterns. 
  • Key drivers and barriers that have a significant impact on the market. 
  • Coverage of pipeline molecules in various phases of drug development. 
  • Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck, Bayer and Warner Chilcott Plc.
  • Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the women’s health therapeutics market.


Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies. 
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10

2 Women’s Health Therapeutics Market to 2018 - Introduction 12
2.1 Overview 12

3 Women’s Health Therapeutics Market to 2018 - Market Overview 13
3.1 Introduction 13
3.2 Revenue Forecasts for the Women’s Health Therapeutics Market 14
3.2.1 Revenues 14
3.2.2 Annual Cost of Therapy 15
3.2.3 Branded and Generic Market Share 16
3.3 Treatment Usage Patterns 17
3.4 Drivers and Barriers for the Women’s Health Therapeutics Market 19
3.4.1 Drivers for the Women’s Health Therapeutics Market 19
3.4.2 Barriers for the Women’s Health Therapeutics Market 19

4 Women’s Health Therapeutics Market to 2018 - Geographical Landscape 20
4.1 The US 20
4.1.1 Revenue 20
4.1.2 Annual Cost of Therapy 21
4.1.3 Treatment Usage Pattern 22
4.2 Top Five Countries of Europe 23
4.2.1 Revenue 23
4.2.2 Annual Cost of Therapy 25
4.2.3 Treatment Usage Pattern 26
4.3 Japan 27
4.3.1 Revenue 27
4.3.2 Annual Cost of Therapy 28
4.3.3 Treatment Usage Pattern 29
4.4 Women’s Health Therapeutics Market, Australia - Overview 30
4.4.1 Epidemiology 30
4.4.2 Clinical Trials 30
4.4.3 Drivers and Restraints 31
4.5 Women’s Health Therapeutics Market, India - Overview 31
4.5.1 Epidemiology 31
4.5.2 Clinical Trials 32
4.5.3 Drivers and Restraints 32
4.6 Women’s Health Therapeutics Market, China - Overview 33
4.6.1 Epidemiology 33
4.6.2 Clinical Trials 33
4.6.3 Drivers and Restraints 34

5 Women’s Health Therapeutics Market to 2018 - Therapeutic Landscape 35
5.1 Menopause 35
5.1.1 Introduction 35
5.1.2 Revenues 36
5.1.3 Branded and Generic Market Share 38
5.1.4 Annual Cost of Therapy 39
5.1.5 Treatment Usage Patterns 40
5.1.6 Major Marketed Products in the Menopause Therapeutics Market 41
5.1.7 Drivers for the Menopause Therapeutics Market 44
5.1.8 Barriers for the Menopause Therapeutics Market 45
5.2 Postmenopausal Osteoporosis 45
5.2.1 Introduction 45
5.2.2 Revenues 46
5.2.3 Branded versus Generic Market Share 48
5.2.4 Annual Cost of Therapy 49
5.2.5 Treatment Usage Patterns 50
5.2.6 Treatment Flow Algorithm 52
5.2.7 Major Marketed Drugs in the Postmenopausal Osteoporosis Market 53
5.2.8 Drivers for the Postmenopausal Osteoporosis Market 60
5.2.9 Barriers for the Postmenopausal Osteoporosis Market 61
5.3 Endometriosis 61
5.3.1 Introduction 61
5.3.2 Revenues 62
5.3.3 Branded and Generic Market Share 64
5.3.4 Annual Cost of Therapy 65
5.3.5 Treatment Usage Patterns 66
5.3.6 Treatment Flow Algorithm 67
5.3.7 Major Marketed Drugs for Endometriosis 68
5.3.8 Drivers for the Endometriosis Therapeutics Market 71
5.3.9 Barriers for the Endometriosis Therapeutics Market 72
5.4 Infertility 72
5.4.1 Introduction 72
5.4.2 Revenues 73
5.4.3 Branded and Generic Market Share 75
5.4.4 Annual Cost of Therapy 76
5.4.5 Treatment Usage Patterns 77
5.4.6 Treatment Flow Algorithm 78
5.4.7 Major Marketed Drugs in the Infertility Therapeutics Market 79
5.4.8 Drivers for the Infertility Therapeutics Market 84
5.4.9 Barriers for the Infertility Therapeutics Market 85
5.5 Female Contraceptives 85
5.5.1 Introduction 85
5.5.2 Revenues 87
5.5.3 Share of Prescription and OTC Contraceptives 90
5.5.4 Annual Cost of Usage 91
5.5.5 Treatment Usage Patterns 92
5.5.6 Major Marketed Products in the Female Contraceptives Market 93
5.5.7 Drivers for the Female Contraceptives Market 95
5.5.8 Barriers for the Female Contraceptives Market 96

6 Women’s Health Therapeutics Market to 2018 - Pipeline Analysis 97
6.1 Overview 97
6.2 Research and Development Pipeline - Menopause 99
6.2.1 Overview 99
6.3 Research and Development Pipeline - Postmenopausal Osteoporosis 99
6.3.1 Overview 99
6.4 Research and Development Pipeline - Endometriosis 100
6.4.1 Overview 100
6.5 Research and Development Pipeline - Infertility 100
6.5.1 Overview 100
6.6 Research and Development Pipeline - Female Sexual Dysfunction 101
6.6.1 Overview 101
6.7 Research and Development Pipeline - Contraceptives 102
6.7.1 Overview 102
6.8 Profiles of Promising Drugs in the Women’s Health Therapeutics Market 103
6.8.1 Menerba 103
6.8.2 Odanacatib 104
6.8.3 Elagolix 105
6.8.4 Libigel 106
6.8.5 Femprox 107
6.8.6 MK 8962 108
6.8.7 Zoely 109
6.8.8 AMG 785 110

7 Women’s Health Therapeutics Market to 2018 - Competitive Landscape 111
7.1 Market Share Analysis: Women’s Health Therapeutics Market 111
7.2 Competitive Profiling 112
7.2.1 Warner Chilcott 112
7.2.2 Pfizer 113
7.2.3 Eli-Lilly 115
7.2.4 Merck 116
7.2.5 Roche 118
7.2.6 Bayer 119

8 Women’s Health Therapeutics Market to 2018 - Strategic Consolidations 120
8.1 Overview 120
8.2 Deals by Year 120
8.3 Deals by Type 121
8.4 Deals by Value 121
8.5 Mergers and Acquisitions 122
8.5.1 Major M&A Deals 124
8.6 Licensing Agreements 125
8.6.1 Major Licensing Agreements 127
8.7 Partnerships 128
8.7.1 Major Partnership Deals 129

9 Women’s Health Therapeutics Market to 2018 - Appendix 130
9.1 Abbreviations 130
9.2 Market Definitions 131
9.3 Bibliography 131
9.4 Research Methodology 132
9.4.1 Coverage 133
9.4.2 Secondary Research 133
9.4.3 Primary Research 133
9.4.4 Expert Panel Validation 134
9.4.5 Section-wise Research Methodology 134
9.5 Therapeutic Landscape 134
9.5.2 Market Size by Geography 136
9.6 Geographical Landscape 137
9.7 Pipeline Analysis 137
9.8 Competitive Landscape 137
9.9 Strategic Consolidations 137
9.10 Contact Us 137
9.11 Disclaimer 137



List of Tables

Table 1: Women’s Health Therapeutics Market, Global, Revenue ($bn), 2003-2011 14
Table 2: Women’s Health Therapeutics Market, Global, Revenue Forecasts ($bn),  2011-2018 14
Table 3: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 15
Table 4: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 15
Table 5: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 17
Table 6: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 17
Table 7: Women’s Health Therapeutics Market, The US, Revenue ($bn), 2003-2011 20
Table 8: Women’s Health Therapeutics Market, The US, Revenue Forecasts ($bn),  2011-2018 20
Table 9: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($),  2003-2011 21
Table 10: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($),  2011-2018 21
Table 11: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2011 22
Table 12: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018 22
Table 13: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2003-2011 23
Table 14: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 24
Table 15: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2011 25
Table 16: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018 25
Table 17: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2011 26
Table 18: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018 26
Table 19: Women’s Health Therapeutics Market, Japan, Revenue ($m), 2003-2011 27
Table 20: Women’s Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018 27
Table 21: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy ($),  2003-2011 28
Table 22: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 28
Table 23: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2011 29
Table 24: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2018 29
Table 25: Women’s Health Therapeutics Market, Pipeline Molecules, Australia, 2012 30
Table 26: Women’s Health Therapeutics Market, Pipeline Molecules, India, 2012 32
Table 27: Women’s Health Therapeutics Market, Pipeline Molecules, China, 2012 33
Table 28: Menopause Therapeutics Market, Global, Revenue ($m), 2003-2011 36
Table 29: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 36
Table 30: Menopause Therapeutics Market, Global, Revenue by Geography ($m),  2003-2011 37
Table 31: Menopause Therapeutics Market, Global, Revenue by Geography ($m),  2011-2018 38
Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($),  2003-2011 39
Table 33: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($),  2011-2018 39
Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 40
Table 35: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million),  2011-2018 40
Table 36: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2003-2011 46
Table 37: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 46
Table 38: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011 47
Table 39: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2011-2018 48
Table 40: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 49
Table 41: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 49
Table 42: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 50
Table 43: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 50
Table 44: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Revenues, 2011 53
Table 45: Endometriosis Therapeutics Market, Global, Revenue ($m), 2003-2011 62
Table 46: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m),  2011-2018 62
Table 47: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011 63
Table 48: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018 64
Table 49: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($),  2003-2011 65
Table 50: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($),  2011-2018 65
Table 51: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 66
Table 52: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 66
Table 53: Infertility Therapeutics Market, Global, Revenue ($m), 2003-2011 73
Table 54: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 73
Table 55: Infertility Therapeutics Market, Global, Revenue by Geography ($m),  2003-2011 74
Table 56: Infertility Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2011-2018 75
Table 57: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011 76
Table 58: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018 76
Table 59: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011 77
Table 60: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018 77
Table 61: Infertility Therapeutics Market, Major Marketed Drug Revenues ($m), 2011 79
Table 62: Efficacy Outcome by Treatment Groups in Ovulation Induction for Study FPI FSH 99-03 (One Cycle of Treatment) 83
Table 63: Efficacy Outcome for IVF Study FPI FSH 2001-01 (One Cycle of Treatment) 84
Table 64: Contraceptives Market, Global, Revenue ($bn), 2003-2011 87
Table 65: Contraceptives Market, Global, Revenue Forecasts ($bn), 2011-2018 87
Table 66: Contraceptives Market, Global, Revenue by Type ($m), 2003-2011 88
Table 67: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2011-2018 88
Table 68: Contraceptives Market, Global, Revenue by Geographical Segmentation ($m),  2003-2011 89
Table 69: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018 90
Table 70: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2011 91
Table 71: Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018 91
Table 72: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2011 92
Table 73: Contraceptives Market, Global, Treatment Usage Patterns (million), 2011-2018 92
Table 74: Contraceptives Market, Major Marketed Drug Market Share, 2011 93
Table 75: Women’s Health Therapeutics Market, Global, Pipeline by Phase (%), 2012 97
Table 76: Women’s Health Therapeutics Market, Global, Pipeline by Indication (%), 2012 98
Table 77: Women’s Health Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules, 2012 103
Table 78: Women’s Health Therapeutics Market, Warner Chilcott, Major Marketed Products, 2011 112
Table 79: Women’s Health Therapeutics Market, Pfizer, Major Marketed Products, 2011 114
Table 80: Women’s Health Therapeutics Market, Eli Lilly, Major Marketed Products, 2011 115
Table 81: Women’s Health Therapeutics Market, Merck, Major Marketed Products, 2011 116
Table 82: Women’s Health Therapeutics Market, Roche, Major Marketed Products, 2011 118
Table 83: Women’s Health Therapeutics Market, Bayer, Major Marketed Products, 2011 119
Table 84: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions, 2010-2012 122
Table 85: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Agreements, 2010-2012 125
Table 86: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Partnerships, 2010-2012 128



List of Figures

Figure 1: Women’s Health Therapeutics Market, Global, Revenue Forecasts ($bn),  2003-2018 14
Figure 2: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 15
Figure 3: Women’s Health Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 16
Figure 4: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 17
Figure 5: Women’s Health Therapeutics Market, Global, Drivers and Barriers 19
Figure 6: Women’s Health Therapeutics Market, The US, Revenue Forecasts ($bn),  2003-2018 20
Figure 7: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2018 21
Figure 8: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2018 22
Figure 9: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2003-2018 23
Figure 10: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2018 25
Figure 11: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2018 26
Figure 12: Women’s Health Therapeutics Market, Japan, Revenue Forecasts ($m),  2003-2018 27
Figure 13: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2018 28
Figure 14: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2018 29
Figure 15: Menopause Therapeutics Market, Global, Revenue Forecasts ($m),  2003-2018 36
Figure 16: Menopause Therapeutics Market, Global, Revenue by Geography ($m),  2003-2018 37
Figure 17: Menopause Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 38
Figure 18: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($),  2003-2018 39
Figure 19: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 40
Figure 20: Menopause Therapeutics Market, Global, Drivers and Barriers 44
Figure 21: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018 46
Figure 22: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2018 47
Figure 23: Postmenopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 48
Figure 24: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 49
Figure 25: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 50
Figure 26: Postmenopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm 52
Figure 27: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Market Share, 2011 53
Figure 28: Postmenopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers 60
Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m),  2003-2018 62
Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018 63
Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 64
Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($),  2003-2018 65
Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 66
Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm 67
Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers 71
Figure 36: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018 73
Figure 37: Infertility Therapeutics Market, Global, Revenue by Geography ($m),  2003-2018 74
Figure 38: Infertility Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018 75
Figure 39: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018 76
Figure 40: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018 77
Figure 41: Infertility Therapeutics Market, Treatment Flow Algorithm 78
Figure 42: Infertility Therapeutics Market, Global, Drivers and Barriers 84
Figure 43: Contraceptives Market, Global, Revenue Forecasts ($bn), 2003-2018 87
Figure 44: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2003-2018 88
Figure 45: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2003-2018 89
Figure 46: Contraceptives Market, Global, Share of Prescription and OTC Contraceptives (%), 2011 90
Figure 47: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2018 91
Figure 48: Contraceptives Market, Global, Treatment Usage Patterns (million),  2003-2018 92
Figure 49: Contraceptives Market, Major Marketed Drug Market Share, 2011 93
Figure 50: Contraceptives Market, Global, Drivers and Barriers 95
Figure 51: Women’s Health Therapeutics Market, Global, Pipeline by Phase (%), 2012 97
Figure 52: Women’s Health Therapeutics Market, Global, Pipeline by Indication (%), 2012 98
Figure 53: Menopause Therapeutics Market, Global, Pipeline by Phase (%), 2012 99
Figure 54: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline by Phase (%), 2012 99
Figure 55: Endometriosis Therapeutics Market, Global, Pipeline by Indication (%), 2012 100
Figure 56: Infertility Therapeutics Market, Global, Pipeline by Indication (%), 2012 100
Figure 57: Female Sexual Dysfunction Therapeutics Market, Global, Pipeline by Indication (%), 2012 101
Figure 58: Female Contraceptives Market, Global, Pipeline by Indication (%), 2012 102
Figure 59: Women’s Health Therapeutics Market, Global, Market Share of Companies (%), 2011 111
Figure 60: Women’s Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2012 113
Figure 61: Women’s Health Therapeutics Market, Pfizer SWOT Analysis, 2012 114
Figure 62: Women’s Health Therapeutics Market, Eli Lilly SWOT Analysis, 2012 115
Figure 63: Women’s Health Therapeutics Market, Merck SWOT Analysis, 2012 117
Figure 64: Women’s Health Therapeutics Market, Roche SWOT Analysis, 2012 118
Figure 65: Women’s Health Therapeutics Market, Bayer SWOT Analysis, 2012 119
Figure 66: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2010-2012 120
Figure 67: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2010-2012 121
Figure 68: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value, 2010-2012 121
Figure 69: GBI Research Market Forecasting Model 136

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3500 View Pricing